Ammar Sarwar

Ammar Sarwar MD is an Associate Professor of Radiology at Harvard Medical School and an interventional radiologist at Beth Israel Deaconess Medical Center in Boston. He performs all types of vascular and non-vascular minimally invasive procedures with a focus on interventional oncology and hepatobiliary interventions.

He is principal investigator of two prospective clinical trials of radioembolization for hepatocellular carcinoma and cholangiocarcinoma. He is also co-director of the BIDMC Liver Tumor Multidisciplinary Program.

Dr. Sarwar is a health services researcher investigating the intersection of costs and outcomes for diagnostic imaging and image-guided procedures in healthcare delivery. His current focus includes time-driven activity based costing for interventional radiology procedures, investigating access to interventional radiology services in the United States, and causes for variations in 30 day readmissions and mortality after interventional radiology procedures in the United States. He is an Associate Editor for the Journal of Vascular and Interventional Radiology. Nationally, Dr. Sarwar serves as an advisor to the American Medical Association's CPT editorial committee, as a member of the Center of Medicare and Medicaid Services (CMS) Medicare Evidence Development and Coverage Advisory Committee, and as a member of CMS MACRA Clinical Care Committee focusing on cost measurement.

Clinical Interests

• Primary Liver Cancer (Hepatocellular Carcinoma and Cholangiocarcinoma)
• Secondary Liver Cancer (e.g. metastatic colorectal cancer or neuroendocrine cancer)
• Portal Hypertension (ascites, variceal bleeding, portal vein thrombosis)
• Liver Transplant and Complex Biliary Interventions
• Lymphatic obstruction and leaks
• Complex Arterial and Aortic Interventions
• Complex Venous Interventions
• Adrenal Venous Sampling
• Cancer ablations and embolizations
• Benign Prostatic Hyperplasia (Prostate Artery Embolization)

Board Certifications

• American Board of Radiology (Interventional & Diagnostic)